Skip to main content
TEYI PHARMACEUTICAL GROUP CO.,LTD logo

TEYI PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002728 ISIN · CNE100001WK6 LEI · 300300ZUIZCFPGQWOZ61 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,596 across all filing types
Latest filing 2024-03-07 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002728

About TEYI PHARMACEUTICAL GROUP CO.,LTD

https://www.tczy.com.cn

TEYI PHARMACEUTICAL GROUP CO.,LTD. specializes in the research, development, manufacturing, and distribution of pharmaceutical products. The company's portfolio primarily consists of Chinese patent medicines and chemical drug preparations. Its flagship product, Zhike Bao Tablets, is widely recognized for treating chronic bronchitis and cough-related ailments. Beyond respiratory health, the group produces a diverse range of medications covering cardiovascular diseases, gastrointestinal disorders, and anti-infective treatments. Teyi Pharmaceutical operates modern production facilities and maintains a robust distribution network to serve healthcare providers and pharmacies. The company emphasizes the integration of traditional medicinal knowledge with modern pharmaceutical technology to enhance product efficacy and safety.

Recent filings

Filing Released Lang Actions
关于会计政策变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding a change in accounting policy by the company 特一药业集团股份有限公司. It references the Ministry of Finance of China and specific accounting standards (《企业会计准则解释第 16 号》) effective from January 1, 2023. The document states that the change is mandated by regulatory requirements and does not require board or shareholder approval. It also mentions that the change will not materially affect financial results. The document is relatively short (1631 characters) and serves as a formal disclosure of the accounting policy change rather than a full financial report or audit report. It does not contain financial statements or detailed financial analysis. Therefore, it is best classified as a Regulatory Filing (RNS), which is the fallback category for regulatory announcements and compliance disclosures that do not fit other specific categories.
2024-03-07 Chinese
独立董事年度述职报告
Board/Management Information Classification · 95% confidence The document is titled as the "2023年度独立董事述职报告" which translates to "2023 Annual Independent Director's Work Report." It is a detailed report by an independent director about their activities, attendance, supervision, and contributions during the year 2023. The content focuses on the director's duties, attendance at board and shareholder meetings, committee work, supervision of company governance, and protection of shareholder rights. It is not an announcement or a brief summary but a substantive report on management oversight and governance activities. This fits best under the category of Board/Management Information (MANG), which covers announcements or reports related to changes or activities of the company's board or senior management. The document is not a full annual report (10-K), audit report (AR), or any other financial or regulatory filing. The length is under 5,000 characters, but the content is a detailed director's report, not a mere announcement. Therefore, the classification is MANG with high confidence.
2024-03-07 Chinese
2023年年度财务报告
Annual Report Classification · 100% confidence The document is titled '2023 年年度财务报告' which translates to '2023 Annual Financial Report'. It contains detailed financial statements including consolidated and parent company balance sheets, profit and loss statements, cash flow statements, and notes. It also includes an audit report with an unqualified opinion from a registered accounting firm dated March 7, 2024. The length of the document is about 15,000 characters, indicating it is a full report rather than a brief announcement. The content includes comprehensive financial data and audit opinions, which are characteristic of an official annual report. Therefore, this document fits the definition of an Annual Report (10-K). FY 2023
2024-03-07 Chinese
2023年年度股东大会资料
AGM Information Classification · 95% confidence The document is titled "2023 年年度股东大会资料" which translates to "2023 Annual General Meeting Materials." It contains detailed reports such as the Board of Directors' work report, Supervisory Board work report, financial statements, and various proposals to be discussed and voted on at the 2023 Annual General Meeting. The content includes summaries of company performance, committee reports, and plans for the next year, all typical of materials prepared for an AGM. There is no indication that this is a full annual report (10-K) or an earnings release (ER). It is not a voting results announcement (DVA) or a proxy solicitation (PSI), but rather the presentation and materials shared during the AGM itself. The document length (15,000 characters) and detailed content confirm it is the AGM materials, not just an announcement or a brief summary. Therefore, the correct classification is AGM Information (AGM-R).
2024-03-07 Chinese
年度募集资金使用鉴证报告
Regulatory Filings
2024-03-07 Chinese
董事会决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 19th meeting of the 5th Board of Directors of 特一药业集团股份有限公司, held on March 7, 2024. It includes approvals of the 2023 Board Work Report, General Manager Work Report, 2023 Financial Statements, Profit Distribution Plan, and the 2023 Annual Report, among others. The document states that these reports and proposals will be submitted to the shareholders' meeting for approval. It also includes voting results and references to the upcoming 2023 Annual Report publication. The document is not the annual report itself but a formal announcement of board meeting decisions and approvals related to governance and financial matters. This fits the definition of Board/Management Information (MANG), which covers announcements of changes or decisions by the board. The document length is under 5,000 characters and does not contain full financial statements or detailed financial data, so it is not an Annual Report (10-K) or Interim Report (IR). It is not a Declaration of Voting Results (DVA) because it is about board meeting resolutions, not shareholder vote results. Therefore, the best classification is MANG with high confidence.
2024-03-07 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.